Marinomed Biotech Ag · VIE:MARI
Marinomed Biotech — FY2021 Earnings Presentation
25 slides from Marinomed Biotech's earnings presentation, Apr 13, 2022
Slide 1: Investor Presentation Full Year 2021
Investor Presentation Full Year 2021 Andreas Grassauer, CEO, Pascal Schmidt, CFO Korneuburg, 13‘ April 2022 Q Marinomed
Slide 2: Disclaimer
Disclaimer This presentation (the “Presentation”) was prepared by Marinomed Biotech AG. The information contained in this Presentation has not been independently verified and no representation or warranty expressed or implied is made as to, and no reliance should be placed on, the fairness, accuracy
Slide 3: Agenda
Agenda * Highlights 2021 Andreas Grassauer, CEO * Financials 2021 Pascal Schmidt, CFO * Marinomed delivered and presents Andreas Grassauer, CEO augmented strategy * Product portfolio * Investment highlights & outlook * Financial calendar, contact ? Marinomed Biotech AG
Slide 4: Highlights 2021
Highlights 2021 Delivering on our promises €11.6M Budesolv Record revenues 1st deal +43% versus 2020 2m USD upfront Tacrosolv Clinical data demonstrate fast onset of action Carragelose Proven neutralization activity against SARS-CoV-2 and VoCs
Slide 5: Agenda
Agenda * Highlights 2021 Andreas Grassauer, CEO ¢ Financials 2021 Pascal Schmidt, CFO * Marinomed delivered and presents Andreas Grassauer, CEO augmented strategy * Product portfolio * Investment highlights & outlook * Financial calendar, contact ? Marinomed Biotech AG
Slide 6: Continuous double digit growth
Continuous double digit growth Strong Carragelose business with upfront from first Marinosolv-deal Y-o-Y comparison of quarterly revenues (m€) 11.6 81 5.9" 10 22 13 10 28 25 31 aa Q2 Q2 Q3 Q3 Q4 Q4 FY FY 2020 2021 2020 2021 2020 2021 2020 2021 2020 2021 Historical performance (revenues and EBIT) 116
Slide 7: Statement of profit or loss (IFRS)
Statement of profit or loss (irrs) Higher revenues — better margins — more R&D invest — improved EBIT FY 2021 | FY 2020 nan) Sale of goods ? Marinomed Biotech AG Note: * includes depreciation & amortisation as well as financial expenses Revenues 16 7 Milestones > 0.0 Other income ® 1.6 1.2 license r
Slide 8: Statement of financial position (IFRS) - Assets
Statement of financial position (irs) Assets €m FY 2021 FY 2020 Assets Intangible assets 2.0 21 Property, plant and equipment ® 64 6.0 Deposits and other non-current 0.0 0.0 Total non-current assets 8.5 8.1 Inventories (2) 10 0.9 Trade and other receivables ® 6.0 5.3 Cash and cash equivalents ® 5.8
Slide 9: Statement of financial position (IFRS) - Equity and liabilities
Statement of financial position (irs) Equity and liabilities em FY2021| FY 2020 Equity and | Share capital 1.5 15 Capital reserves © 421 4.4 Accumulated deficit -43.4 -37.5 Total capital and reserves 0.2 5.4 Borrowings ® 15.0 12.5 Other non-current liabilities 01 Ol Total non-current liabilities 15.
Slide 10: Agenda
Agenda * Highlights 2021 Andreas Grassauer, CEO * Financials 2021 Pascal Schmidt, CFO * Marinomed delivered and presents augmented strategy * Product portfolio * Investment highlights & outlook Andreas Grassauer, CEO * Financial calendar, contact ? Marinomed Biotech AG 10
Slide 11: Marinomed achievements
Marinomed achievements Towards higher values ° Carragelose Corporate virus blocker 2006: 2008: Founding and first financing Clinically validated 2017: 2010 - 2012: Convertible bond (€7m) at €20m Further clinical studies, incl. in valuation children (1 year and older) 2019: 2020: IPO and EIB financin
Slide 12: Strategy 2025
Strategy 2025 + Viral - pneumonia FOCUS THERAPEUTIC AREAS VIROLOGY 2022 and beyond Onp Q? Carragelose marketed 2006 - 2021 © Marinomed Biotech AG + Anterior eye diseases + Inflammatory gastrointestinal diseases 6 IMMUNOLOGY Budesolv partnered 12
Slide 13: Strategy 2025: Key initiatives 2022
Strategy 2025 Key initiatives 2022 - more to come Therapeutic area: Virology Viral infectious diseases Therapeutic area: Immunology Autoreactive immune disorders Besides viral pneumonia, Marinomed has started an additional program that targets a potentially life-threatening disease caused by viruses
Slide 14: Pipeline overview
Pipeline overview Therapeutic Area Product Indication Status RX SEGMENT —— Immunology Tacrosolv Anterior inflammatory Phase 2 eye diseases clinical trial locally applied Autoimmune gastritis Preclinical —<—= steroid Virology Inhaleen Viral pneunomia Phase! Giinieal trial ————— OTC SEGMENT ° ° ° ° Im
Slide 15: INHALeeN — inhalable broad-spectrum antiviral
INHALeeN — inhalable broad-spectrum antiviral Addressing the global need for improved treatment options for respiratory infections across virus families ? Marinomed Biotech AG Pandemic Endemic Global consecutive waves Regional seasonal waves up to several years every year E.g., SARS-CoV-2, influenza
Slide 16: INHALeeN
INHALeeN A potential first-in-class pharmaceutical for prophylaxis and therapy at the onset of outbreaks + Inhibition of replication of SARS-CoV-2 and its VoCs as well as rhinoviruses, Scientific evidence influenza, RSV, hMPV, PIV and adenoviruses demonstrated in-vitro * Clinical study with inhalabl
Slide 17: Budesolv
Budesolv First deal for Chinese territory - more business development to do First deal generated first milestone payment Establish production Activities at Chinese partner Focus 2022 at Marinomed Register ingredients in territory * Additional regulatory preparations and partnering activities ongoing
Slide 18: Tacrosolv
Tacrosolv Best in class macrolide immunosuppressant — fully solubilized with Marinosolv® technology Solubilized Tacrolimus (Liquid formulation) Micelle enabled solubilization in aqueous Marinosolv formulation . Tacrolimus is a macrolide calcineurin inhibitor Practically insoluble in water ~100 times
Slide 19: Tacrosolv — primary indication
Tacrosolv — primary indication Target population & market sizes — offering the potential for the treatment of several inflammatory anterior eye diseases Tacrosolv — assessed target diseases ! : A F aya Herpetic stromal Cornea Dry eye disease Allergic conjunctivitis ree transplantation * Many patient
Slide 20: Investment Highlights
nvestment Highlights Target therapeutic areas Virology Immunology Achievements * lota-carrageenan is effective against SARS-CoV-2 and all prevalent variants of concern * Proven track record — safe, top tier partners, partnered in more than 40 countries, generating margins Next steps * Target more se
Slide 21: Strong outlook for 2022 and beyond
Strong outlook for 2022 and beyond Both therapeutic areas offer significant upside potential “Ss Business development ® — organization ©0® + INHALeeN as first Rx product in * Carragelose allows for additional * Moving to Rx as key value driver viral infectious diseases partnerships/ product launches
Slide 22: Agenda
Agenda * Highlights 2021 Andreas Grassauer, CEO * Financials 2021 Pascal Schmidt, CFO * Marinomed delivered and presents augmented strategy * Product portfolio * Investment highlights & outlook Andreas Grassauer, CEO ¢ Financial calendar, contact ? Marinomed Biotech AG 22
Slide 23: Financial calendar & IR contact
Financial calendar & IR contact Financial Calendar Stephanie Kniep April 13, 2022 Publication of the Annual Report 2021 Investor Relations phone: +43 2262 90300 226 May 23, 2022 Publication of the Results QI] 2022 a, 5 e-mail: IR@marinomed.com June 5, 2022 Record date AGM June 15, 2022 AGM August 25
Slide 24: Thank you!
Thank you! 24
Slide 25: Carragelose
Carragelose SARS-CoV-2 will evolve and evade immunity Expected future developments 1. Ongoing manifestations of severe disease with high levels of infection 2. Transition to an epidemic seasonal disease like influenza 3. Transition into an endemic disease similar to other coronavirus infections CARR